Achieving flexibility and scalability in cell therapy manufacturing through optimized cell isolation and activation

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Achieving flexibility and scalability in cell therapy manufacturing through optimized cell isolation and activation

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Cell therapy is one of the most exciting and dynamic fields in modern medicine. Yet there are still challenges such as reducing manufacturing timeframes and maintaining consistent performance in light of patient variability. Thermo Fisher Scientific is releasing a first-of-its-kind platform technology that enables isolation and activation of T cells in one step with a key differentiator: an active release mechanism for clinical trial or commercial manufacturing. The Gibco™ CTS™ Detachable Dynabeads™ CD3/CD28 Kit possesses a proprietary active release mechanism that enables the intentional early release of Dynabeads from the cells before the naturally occurring release at day 4 or 5. Conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation markers, the performance exhibits consistent and optimal isolation, activation, and purity of target T cell populations while addressing the biological variability that cell therapy manufacturers are facing.

Attend this webinar to learn about:

How the active detachment of Dynabeads from target cells at any time allows users to add flexibility and scalability to their process
How to maintain desired cell phenotypes
Suitability for both autologous and allogeneic processes

Eugene Kang

Product Manager at Thermo Fisher Scientific

Eugene Kang is a Senior Product Manager at Thermo Fisher Scientific with a personal desire to establish cell therapy as a first-line treatment worldwide. He joined the company in 2015 after earning a Master of Business Administration at Boston University but prior to that, was a published academic researcher for eight years in the field of Alzheimer’s disease research. With a bachelor’s degree from the University of Notre Dame and a Master of Public Health from Columbia University, Eugene has developed his career with a focus on optimizing patient safety, efficacy, and access.